東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

FindBook

Google Book

Amazon

博客來

Biopharma in China = innovation, trends and dealmaking /

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Biopharma in China/ by Sven Agten, Ben Wu.
其他題名:	innovation, trends and dealmaking /
作者:	Agten, Sven.
其他作者:	Wu, Ben.
出版者:	Singapore :Springer Nature Singapore : : 2024.,
面頁冊數:	vii, 155 p. :ill. (some col.), digital ;24 cm.
內容註:	Chapter 1: The Chinese healthcare and pharmaceutical market: Ignore at your own peril -- Chapter 2: China regulatory and legal reforms: Gateway to innovation and global integration -- Chapter 3: The golden age of the Chinese biopharma: Explosive growth in a thriving ecosystem -- Chapter 4: Innovation in the Chinese biopharma: From me-too to First-in-class -- Chapter 5: The art of the biopharma deal: The China angle -- Chapter 6: End if the first cycle. A drastic rest, future challenges and opportunities.
Contained By:	Springer Nature eBook
標題:	Pharmaceutical biotechnology industry - China. -
電子資源:	https://doi.org/10.1007/978-981-97-1471-1
ISBN:	9789819714711

Biopharma in China = innovation, trends and dealmaking /
Agten, Sven.

Biopharma in Chinainnovation, trends and dealmaking /[electronic resource] :by Sven Agten, Ben Wu. - Singapore :Springer Nature Singapore :2024. - vii, 155 p. :ill. (some col.), digital ;24 cm.

Chapter 1: The Chinese healthcare and pharmaceutical market: Ignore at your own peril -- Chapter 2: China regulatory and legal reforms: Gateway to innovation and global integration -- Chapter 3: The golden age of the Chinese biopharma: Explosive growth in a thriving ecosystem -- Chapter 4: Innovation in the Chinese biopharma: From me-too to First-in-class -- Chapter 5: The art of the biopharma deal: The China angle -- Chapter 6: End if the first cycle. A drastic rest, future challenges and opportunities.

This book provides an insider's overview of the emerging Chinese biopharma sector, its dynamics and trends, first bust and boom cycle, long-term perspectives, and how as a foreign company or investor to tap into this. China has gone from a country with no innovation in drug discovery, to a country which starts to out-license its biopharma technology to the rest of the world. The Chinese biopharma sector is only a decade old, but it already has become a new driver of growth and value. The book takes a closer look at what drives Chinese innovation in the biopharma sector, how to deal with this innovation, and what opportunities and challenges this provides for foreign companies. The book also takes a deep dive into its first biopharma boom and bust cycle, and what it means for the sector. It also explains what deals Chinese biopharma companies and investors are looking for, what works and what doesn't, and how as a foreign company can tap into the world's second largest healthcare market. Ben Wu has close to 30 years of experience in the pharmaceutical industry, holding senior executive positions in the Asia Pacific region for multinationals like J&J and Sanofi. He was active in several China originated biopharma companies, and is the founding CEO of Citrine Medicine, a venture capital backed biopharma. Originally from Belgium, Sven Agten has been living and working in China since 2004. He is a seasoned business executive working for SMEs and multinationals, with in-depth experience about business in China. He has published several books about China, all related to China business challenges, trends and opportunities.

ISBN: 9789819714711

Standard No.: 10.1007/978-981-97-1471-1doiSubjects--Topical Terms:

3715099
Pharmaceutical biotechnology industry
--China.

LC Class. No.: HD9672.C52

Dewey Class. No.: 338.4761530951

Biopharma in China = innovation, trends and dealmaking /
LDR:03182nmm a22003375a 4500 001 2370039
003 DE-He213
005 20240417100358.0
006 m d
007 cr nn 008maaau
008 241127s2024 si s 0 eng d
020 $a 9789819714711 $q (electronic bk.)
020 $a 9789819714704 $q (paper)
024 7 $a 10.1007/978-981-97-1471-1 $2 doi
035 $a 978-981-97-1471-1
040 $a GP $c GP
041 0 $a eng
050 4 $a HD9672.C52
072 7 $a KC $2 bicssc
072 7 $a 1F $2 bicssc
072 7 $a BUS035000 $2 bisacsh
072 7 $a KC $x 1F $2 thema
082 0 4 $a 338.4761530951 $2 23
090 $a HD9672.C52 $b A281 2024
100 1 $a Agten, Sven. $3 3494148
245 1 0 $a Biopharma in China $h [electronic resource] : $b innovation, trends and dealmaking / $c by Sven Agten, Ben Wu.
260 $a Singapore : $b Springer Nature Singapore : $b Imprint: Palgrave Macmillan, $c 2024.
300 $a vii, 155 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Chapter 1: The Chinese healthcare and pharmaceutical market: Ignore at your own peril -- Chapter 2: China regulatory and legal reforms: Gateway to innovation and global integration -- Chapter 3: The golden age of the Chinese biopharma: Explosive growth in a thriving ecosystem -- Chapter 4: Innovation in the Chinese biopharma: From me-too to First-in-class -- Chapter 5: The art of the biopharma deal: The China angle -- Chapter 6: End if the first cycle. A drastic rest, future challenges and opportunities.
520 $a This book provides an insider's overview of the emerging Chinese biopharma sector, its dynamics and trends, first bust and boom cycle, long-term perspectives, and how as a foreign company or investor to tap into this. China has gone from a country with no innovation in drug discovery, to a country which starts to out-license its biopharma technology to the rest of the world. The Chinese biopharma sector is only a decade old, but it already has become a new driver of growth and value. The book takes a closer look at what drives Chinese innovation in the biopharma sector, how to deal with this innovation, and what opportunities and challenges this provides for foreign companies. The book also takes a deep dive into its first biopharma boom and bust cycle, and what it means for the sector. It also explains what deals Chinese biopharma companies and investors are looking for, what works and what doesn't, and how as a foreign company can tap into the world's second largest healthcare market. Ben Wu has close to 30 years of experience in the pharmaceutical industry, holding senior executive positions in the Asia Pacific region for multinationals like J&J and Sanofi. He was active in several China originated biopharma companies, and is the founding CEO of Citrine Medicine, a venture capital backed biopharma. Originally from Belgium, Sven Agten has been living and working in China since 2004. He is a seasoned business executive working for SMEs and multinationals, with in-depth experience about business in China. He has published several books about China, all related to China business challenges, trends and opportunities.
650 0 $a Pharmaceutical biotechnology industry $z China. $3 3715099
650 1 4 $a Asian Economics. $3 2191385
650 2 4 $a Biomedical Research. $3 851895
650 2 4 $a Economics of Innovation. $3 3591766
700 1 $a Wu, Ben. $3 3715098
710 2 $a SpringerLink (Online service) $3 836513
773 0 $t Springer Nature eBook
856 4 0 $u https://doi.org/10.1007/978-981-97-1471-1
950 $a Economics and Finance (SpringerNature-41170)